semaglutide diabetes type 1 united states Wegovy® access expanded for Medicare beneficiaries living with obesity through the Medicare GLP-1 Bridge starting July 1, 2026 Half of Patients Stop Semaglutide

Unlike existing therapies that target one or two hormonal pathways, Retatrutide is a triple agonist , simultaneously activating three key receptors: GLP-1 (Glucagon-Like Peptide-1) Receptor : Enhances insulin secretion, suppresses appetite, and slows gastric emptying

Ponce, R

At least 297 prescriptions were made from five different lots of weight-loss drugs that hadnt been tested properly

Zhang C, Chen C, Hu H, Yan X

If you experience persistent vomiting or diarrhea, do not push through it

For information on diagnosing suspicious skin lesions using dermatoscopy see: Diagnosing solar keratoses and non-melanoma skin cancer using dermatoscopy